



GSHISHIMA@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3081

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

1696
RECEIVED

APR 15 2002

TECH CENTER 1600/2900

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

April 3, 2002

COPY OF PAPERS
ORIGINALLY FILED

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

April 3, 2002
Date


Gina N. Shishima

Commissioner for Patents
Washington, D.C. 20231

Re: SN 09/418,095 entitled "THIAZOLIDINEDIONES ALONE OR IN COMBINATION WITH OTHER THERAPEUTIC AGENTS FOR TUMOR THERAPY" by Copland et al.
Our file UTSG:239/10018876 Client file UTMB/GAL:239


Commissioner:

Enclosed for filing in the above-referenced patent application is:

- (1) Amendment and Response to Office Action dated January 3, 2002; and
- (2) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10018876/GNS.

Very truly yours,


Gina N. Shishima
Reg No. 45,104

GNS/lb
Enclosures

25152061.1

COPY OF PAPERS
ORIGINALLY FILED

#10/B
RB
a/25/02

RECEIVED

APR 15 2002

TECH CENTER 1600/2900



CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on the date below:	
April 3, 2002 Date	 Gina N. Shishima

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

John A. Copland, III
Slavisa Gasic
Randall J. Urban
Melvyn Soloff

Group Art Unit: 1646

Examiner: Nguyen, Q.

Atty. Dkt. No.: UTSG:239/SHS

Serial No.: 09/418,095

Filed: October 14, 1999

For: THIAZOLIDINEDIONES IN
COMBINATION WITH OTHER
THERAPEUTIC AGENTS FOR TUMOR
THERAPY (AS AMENDED)

I. AMENDMENT; AND

II. RESPONSE TO OFFICE ACTION DATED JANUARY 3, 2002

Commissioner for Patents
Washington, D.C. 20231

Commissioner:

This paper is submitted in response to the Office Action dated January 3, 2002 for which the three-month date for response is April 3, 2002. It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, the Commissioner is authorized to withdraw the appropriate fee from Fulbright & Jaworski Deposit Account No. 50-1212/10018876/GNS.